

Glenda M Macqueen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8785632/publications.pdf>

Version: 2024-02-01

128
papers

10,892
citations

53794

45
h-index

32842

100
g-index

128
all docs

128
docs citations

128
times ranked

11106
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebello-cerebral Functional Connectivity Networks in Major Depressive Disorder: a CAN-BIND-1 Study Report. <i>Cerebellum</i> , 2023, 22, 26-36.	2.5	0
2	Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2023, 68, 299-311.	1.9	5
3	Childhood trauma and amygdala nuclei volumes in youth at risk for mental illness. <i>Psychological Medicine</i> , 2022, 52, 1192-1199.	4.5	22
4	Baseline Functional Connectivity in Resting State Networks Associated with Depression and Remission Status after 16 Weeks of Pharmacotherapy: A CAN-BIND Report. <i>Cerebral Cortex</i> , 2022, 32, 1223-1243.	2.9	6
5	Cerebello-limbic functional connectivity patterns in youth at clinical high risk for psychosis. <i>Schizophrenia Research</i> , 2022, 240, 220-227.	2.0	6
6	Clinical staging for youth at risk for serious mental illness: A longitudinal perspective. <i>Microbial Biotechnology</i> , 2021, 15, 1188-1196.	1.7	6
7	Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110194.	4.8	11
8	Brain aging in major depressive disorder: results from the ENIGMA major depressive disorder working group. <i>Molecular Psychiatry</i> , 2021, 26, 5124-5139.	7.9	136
9	Pilot aerobic exercise intervention for youth at risk for serious mental illness. <i>Microbial Biotechnology</i> , 2021, 15, 547-553.	1.7	5
10	Substance use in youth at risk for serious mental illness. <i>Microbial Biotechnology</i> , 2021, 15, 634-641.	1.7	1
11	Personality and risk for serious mental illness. <i>Microbial Biotechnology</i> , 2021, 15, 133-139.	1.7	5
12	Longitudinal Trends in Medication Treatment for Youth At-Risk for Serious Mental Illness. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 418-420.	1.9	1
13	Multisite Comparison of MRI Defacing Software Across Multiple Cohorts. <i>Frontiers in Psychiatry</i> , 2021, 12, 617997.	2.6	32
14	Recruitment Challenges for Studies of Deep Brain Stimulation for Treatment-Resistant Depression. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 765-775.	2.2	5
15	Exploring brain connectivity changes in major depressive disorder using functional-structural data fusion: A CAN-BIND-1 study. <i>Human Brain Mapping</i> , 2021, 42, 4940-4957.	3.6	8
16	Resting state fMRI scanner instabilities revealed by longitudinal phantom scans in a multi-center study. <i>NeuroImage</i> , 2021, 237, 118197.	4.2	5
17	Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report. <i>Psychoneuroendocrinology</i> , 2021, 132, 105348.	2.7	8
18	Cognition and Its Association with Psychosocial and Occupational Functioning during Treatment with Escitalopram in Patients with Major Depressive Disorder: A CAN-BIND-1 Report: La Cognition Et Son Association Avec Le Fonctionnement Psychosocial Et Professionnel Durant Le Traitement Par Escitalopram Chez Des Patients Souffrant De Trouble Dépressif Majeur: Une Étude Can-Bind-1. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 798-806.	1.9	0

#	ARTICLE	IF	CITATIONS
19	Magnetic Resonance Imaging Sequence Identification Using a Metadata Learning Approach. <i>Frontiers in Neuroinformatics</i> , 2021, 15, 622951.	2.5	2
20	Childhood maltreatment and cognitive functioning in patients with major depressive disorder: a CAN-BIND-1 report. <i>Psychological Medicine</i> , 2020, 50, 2536-2547.	4.5	17
21	Social and role functioning in youth at risk of serious mental illness. <i>Microbial Biotechnology</i> , 2020, 14, 463-469.	1.7	8
22	Sleep disturbances in youth at risk for serious mental illness. <i>Microbial Biotechnology</i> , 2020, 14, 373-378.	1.7	14
23	Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report. <i>Neuropsychopharmacology</i> , 2020, 45, 283-291.	5.4	37
24	Trauma in Youth At-Risk for Serious Mental Illness. <i>Journal of Nervous and Mental Disease</i> , 2020, 208, 70-76.	1.0	7
25	Yoga as a Therapy for Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2503-2514.	2.3	24
26	Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study. <i>Journal of Affective Disorders</i> , 2020, 264, 414-424.	4.1	6
27	Reliability of a functional magnetic resonance imaging task of emotional conflict in healthy participants. <i>Human Brain Mapping</i> , 2020, 41, 1400-1415.	3.6	7
28	Aerobic exercise and hippocampal change in youth at risk of serious mental illness. <i>Psychiatry Research - Neuroimaging</i> , 2020, 305, 111199.	1.8	0
29	Functional imaging in youth at risk for transdiagnostic serious mental illness: Initial results from the PROCAN study. <i>Microbial Biotechnology</i> , 2020, 15, 1276-1291.	1.7	3
30	Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. <i>Neuropsychopharmacology</i> , 2020, 45, 1390-1397.	5.4	23
31	White Matter Connectivity in Youth at Risk for Serious Mental Illness: A Longitudinal Analysis. <i>Psychiatry Research - Neuroimaging</i> , 2020, 302, 111106.	1.8	4
32	The relationship between depression risk perception and self-help behaviours in high risk Canadians: a cross-sectional study. <i>BMC Public Health</i> , 2020, 20, 876.	2.9	4
33	The accuracy of depression risk perception in high risk Canadians. <i>Journal of Affective Disorders</i> , 2020, 265, 410-415.	4.1	7
34	An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report. <i>NeuroImage: Clinical</i> , 2020, 25, 102178.	2.7	10
35	Aberrant limbic brain structures in young individuals at risk for mental illness. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 294-302.	1.8	14
36	Intrinsic thalamocortical connectivity varies in the age of onset subtypes in major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 75-82.	2.2	13

#	ARTICLE	IF	CITATIONS
37	Treatment History of Youth At-Risk for Serious Mental Illness. Canadian Journal of Psychiatry, 2019, 64, 145-154.	1.9	8
38	Cortical thickness in major depressive disorder: A systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 88, 287-302.	4.8	113
39	Reduced accuracy accompanied by reduced neural activity during the performance of an emotional conflict task by unmedicated patients with major depression: A CAN-BIND fMRI study. Journal of Affective Disorders, 2019, 257, 765-773.	4.1	20
40	A randomized controlled trial to examine the impacts of disclosing personalized depression risk information on the outcomes of individuals who are at high risk of developing major depression: a research protocol. BMC Psychiatry, 2019, 19, 285.	2.6	8
41	White Matter Indices of Medication Response in Major Depression: A Diffusion Tensor Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 913-924.	1.5	21
42	Clinical staging for youth at-risk for serious mental illness. Microbial Biotechnology, 2019, 13, 1416-1423.	1.7	42
43	Patient Engagement and Multidisciplinary Involvement Has an Impact on Clinical Guideline Development and Decisions: A Comparison of Two Irritable Bowel Syndrome Guidelines Using the Same Data. Journal of the Canadian Association of Gastroenterology, 2019, 2, 30-36.	0.3	7
44	Testing a deep convolutional neural network for automated hippocampus segmentation in a longitudinal sample of healthy participants. NeuroImage, 2019, 197, 589-597.	4.2	24
45	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). Journal of the Canadian Association of Gastroenterology, 2019, 2, 6-29.	0.3	104
46	Association between solar insolation and a history of suicide attempts in bipolar I disorder. Journal of Psychiatric Research, 2019, 113, 1-9.	3.1	25
47	Altered hippocampal function with preserved cognitive performance in treatment-naive major depressive disorder. NeuroReport, 2019, 30, 46-52.	1.2	3
48	Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. Psychological Medicine, 2019, 49, 1629-1638.	4.5	22
49	Aerobic exercise in depressed youth: A feasibility and clinical outcomes pilot. Microbial Biotechnology, 2019, 13, 128-132.	1.7	13
50	The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols. Journal of Psychiatry and Neuroscience, 2019, 44, 223-236.	2.4	37
51	Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2019, 80, .	2.2	61
52	Canadian Network for Mood and Anxiety Treatments (<sc>CANMAT</sc>) and International Society for Bipolar Disorders (<sc>ISBD</sc>) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 2018, 20, 97-170.	1.9	1,079
53	Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient. International Journal of Neuropsychopharmacology, 2018, 21, 128-144.	2.1	68
54	Neuroimaging biomarkers as predictors of treatment outcome in Major Depressive Disorder. Journal of Affective Disorders, 2018, 233, 21-35.	4.1	124

#	ARTICLE	IF	CITATIONS
55	Neurocognitive deficits in a transdiagnostic clinical staging model. <i>Psychiatry Research</i> , 2018, 270, 1137-1142.	3.3	17
56	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i>, Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 1173-1182.	2.3	18
57	Family functioning in youth at-risk for serious mental illness. <i>Comprehensive Psychiatry</i> , 2018, 87, 17-24.	3.1	16
58	Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder. <i>Frontiers in Psychiatry</i> , 2018, 9, 207.	2.6	28
59	Youth at-risk for serious mental illness: methods of the PROCAN study. <i>BMC Psychiatry</i> , 2018, 18, 219.	2.6	29
60	A novel task for examining the neural basis of Theory of Mind deficits in bipolar disorder. <i>Psychiatry Research - Neuroimaging</i> , 2018, 282, 143-150.	1.8	4
61	Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression Guidelines. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 77-78.	1.9	0
62	Thalamocortical connectivity in major depressive disorder. <i>Journal of Affective Disorders</i> , 2017, 217, 125-131.	4.1	70
63	Response to Letter Regarding CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 353-354.	1.9	0
64	A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder. <i>Journal of Affective Disorders</i> , 2017, 210, 57-65.	4.1	42
65	Methylene blue treatment for residual symptoms of bipolar disorder: Randomised crossover study. <i>British Journal of Psychiatry</i> , 2017, 210, 54-60.	2.8	44
66	Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 11-23.	1.9	90
67	Cognitive dysfunction in major depression and bipolar disorder: <scp>A</scp>ssessment and treatment options. <i>Psychiatry and Clinical Neurosciences</i> , 2017, 71, 18-27.	1.8	131
68	The gut microbiota and psychiatric illness. <i>Journal of Psychiatry and Neuroscience</i> , 2017, 42, 75-77.	2.4	28
69	Pregnant Womenâ€™s Views on the Feasibility and Acceptability of Web-Based Mental Health E-Screening Versus Paper-Based Screening: A Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2017, 19, e88.	4.3	35
70	Pregnant Womenâ€™s Perceptions of the Risks and Benefits of Disclosure During Web-Based Mental Health E-Screening Versus Paper-Based Screening: Randomized Controlled Trial. <i>JMIR Mental Health</i> , 2017, 4, e42.	3.3	12
71	Functional Recovery in Major Depressive Disorder. primary care companion for CNS disorders, <i>The</i> , 2016, 18, .	0.6	51
72	Amygdala responses to quetiapine XR and citalopram treatment in major depression: the role of 5â€™HTTLPRâ€™/Lg polymorphisms. <i>Human Psychopharmacology</i> , 2016, 31, 144-155.	1.5	12

#	ARTICLE	IF	CITATIONS
73	Cortical thickness and emotion processing in young adults with mild to moderate depression: a preliminary study. BMC Psychiatry, 2016, 16, 38.	2.6	29
74	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 506-509.	1.9	58
75	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 588-603.	1.9	165
76	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 510-523.	1.9	209
77	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 540-560.	1.9	746
78	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 524-539.	1.9	340
79	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 561-575.	1.9	415
80	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 576-587.	1.9	227
81	Neonatal Outcomes in Women With Untreated Antenatal Depression Compared With Women Without Depression. JAMA Psychiatry, 2016, 73, 826.	11.0	326
82	Mental Health Services for Students at Postsecondary Institutions: A National Survey. Canadian Journal of Psychiatry, 2016, 61, 766-775.	1.9	47
83	Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry, 2016, 16, 105.	2.6	114
84	Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet, The, 2016, 387, 1085-1093.	13.7	306
85	Subgenual anterior cingulate cortex and hippocampal volumes in depressed youth: The role of comorbidity and age. Journal of Affective Disorders, 2016, 190, 726-732.	4.1	55
86	Pregnancy-related anxiety: A concept analysis. International Journal of Nursing Studies, 2016, 55, 115-130.	5.6	150
87	Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression. Journal of Visualized Experiments, 2015, , e52061.	0.3	1
88	Adolescence as a unique developmental period. Journal of Psychiatry and Neuroscience, 2015, 40, 291-293.	2.4	179
89	Influence of light exposure during early life on the age of onset of bipolar disorder. Journal of Psychiatric Research, 2015, 64, 1-8.	3.1	39
90	Assessing personal financial management in patients with bipolar disorder and its relation to impulsivity and response inhibition. Cognitive Neuropsychiatry, 2015, 20, 424-437.	1.3	9

#	ARTICLE	IF	CITATIONS
91	A review of fMRI studies during visual emotive processing in major depressive disorder. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 448-471.	2.6	102
92	Combined treatment: impact of optimal psychotherapy and medication in bipolar disorder. <i>Bipolar Disorders</i> , 2015, 17, 86-96.	1.9	19
93	Prophylactic lithium treatment and cognitive performance in patients with a long history of bipolar illness: no simple answers in complex disease-treatment interplay. <i>International Journal of Bipolar Disorders</i> , 2014, 2, 1.	2.2	28
94	Comparing the feasibility, acceptability, clinical-, and cost-effectiveness of mental health e-screening to paper-based screening on the detection of depression, anxiety, and psychosocial risk in pregnant women: a study protocol of a randomized, parallel-group, superiority trial. <i>Trials</i> , 2014, 15, 3.	1.6	13
95	Alterations in empathic responding among women with posttraumatic stress disorder associated with childhood trauma. <i>Brain and Behavior</i> , 2014, 4, 381-389.	2.2	52
96	Relationship between sunlight and the age of onset of bipolar disorder: An international multisite study. <i>Journal of Affective Disorders</i> , 2014, 167, 104-111.	4.1	43
97	A Survey of Mental Health Services at Post-Secondary Institutions in Alberta. <i>Canadian Journal of Psychiatry</i> , 2014, 59, 250-258.	1.9	23
98	Psychological factors that may confer risk for bipolar disorder. <i>Cognitive Neuropsychiatry</i> , 2013, 18, 115-128.	1.3	15
99	Changes in cortical thickness across the lifespan in major depressive disorder. <i>Psychiatry Research - Neuroimaging</i> , 2013, 214, 204-211.	1.8	59
100	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. <i>American Journal of Psychiatry</i> , 2013, 170, 1249-1262.	7.2	579
101	Neural correlates of cognitive remediation in patients with mood disorders. <i>Psychiatry Research - Neuroimaging</i> , 2013, 214, 142-152.	1.8	55
102	Theory of mind deficits in patients with mild symptoms of major depressive disorder. <i>Psychiatry Research</i> , 2013, 210, 672-674.	3.3	49
103	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. <i>Bipolar Disorders</i> , 2013, 15, 1-44.	1.9	740
104	Psychosocial Interventions for Bipolar Disorder and Coping Style Modification: Similar Clinical Outcomes, Similar Mechanisms?. <i>Canadian Journal of Psychiatry</i> , 2013, 58, 482-486.	1.9	11
105	Neuroimaging and electrophysiology in predicting treatment responsiveness in depression: bridging the lab-to-clinic divide?. <i>Canadian Journal of Psychiatry</i> , 2013, 58, 497-8.	1.9	1
106	Systematic review of the neural basis of social cognition in patients with mood disorders. <i>Journal of Psychiatry and Neuroscience</i> , 2012, 37, 154-169.	2.4	172
107	Predicting Hospital Length of Stay for Geriatric Patients with Mood Disorders. <i>Canadian Journal of Psychiatry</i> , 2012, 57, 627-634.	1.9	1
108	Patients with bipolar disorder show impaired performance on complex tests of social cognition. <i>Psychiatry Research</i> , 2012, 200, 258-264.	3.3	44

#	ARTICLE	IF	CITATIONS
109	A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. <i>Bipolar Disorders</i> , 2012, 14, 697-706.	1.9	81
110	An Update on Antidepressant Use in Bipolar Depression. <i>Current Psychiatry Reports</i> , 2012, 14, 696-704.	4.5	47
111	A Randomized Controlled Trial of Psychoeducation or Cognitive-Behavioral Therapy in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 803-810.	2.2	111
112	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid personality disorders. <i>Annals of Clinical Psychiatry</i> , 2012, 24, 56-68.	0.6	25
113	A review of factors that moderate autobiographical memory performance in patients with major depressive disorder. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2010, 32, 1122-1144.	1.3	48
114	Altered self-report of empathic responding in patients with bipolar disorder. <i>Psychiatry Research</i> , 2010, 178, 354-358.	3.3	56
115	Impaired theory of mind performance in patients with recurrent bipolar disorder: Moderating effect of cognitive load. <i>Psychiatry Research</i> , 2010, 177, 261-262.	3.3	38
116	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. <i>Bipolar Disorders</i> , 2009, 11, 225-255.	1.9	545
117	Magnetic resonance imaging and prediction of outcome in patients with major depressive disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2009, 34, 343-9.	2.4	64
118	Posterior Hippocampal Volumes Are Associated with Remission Rates in Patients with Major Depressive Disorder. <i>Biological Psychiatry</i> , 2008, 64, 880-883.	1.3	224
119	Reply: "Lithium and Increased Hippocampal Volume: More Tissue or More Water?". <i>Neuropsychopharmacology</i> , 2008, 33, 1775-1775.	5.4	1
120	Galantamine as an Adjunctive Treatment in Major Depression. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 357-359.	1.4	21
121	The impact of personality disorders on treatment outcome in bipolar disorder: A review. <i>Personality and Mental Health</i> , 2007, 1, 2-13.	1.2	10
122	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. <i>Bipolar Disorders</i> , 2006, 8, 721-739.	1.9	202
123	Associations Between Bipolar Disorder and Metabolic Syndrome. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1034-1041.	2.2	135
124	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. <i>Bipolar Disorders</i> , 2005, 7, 5-69.	1.9	321
125	A review of psychosocial outcome in patients with bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2001, 103, 163-170.	4.5	286
126	Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2000, 101, 374-381.	4.5	130

#	ARTICLE	IF	CITATIONS
127	Double-Blind Comparison of Addition of a Second Mood Stabilizer Versus an Antidepressant to an Initial Mood Stabilizer for Treatment of Patients With Bipolar Depression. American Journal of Psychiatry, 2000, 157, 124-126.	7.2	207
128	A two-illness model of bipolar disorder 1. Bipolar Disorders, 1999, 1, 25-30.	1.9	51